ArticleHarm reduction journal2026
'A fine line between euphoria and death': a qualitative study exploring gamma-hydroxybutyrate (GHB) use among people who identify as heterosexual living in Australia.
Article in Harm reduction journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHarms associated with gamma-hydroxybutyrate (GHB) use have increased recently in Australia. However, research predominantly focuses on the experience of GHB use among LGBTQ + populations. Non-prescribed GHB use has not been well described in heterosexual populations. Research to examine the experience of heterosexual people, including motivations for use, experiences of harms, and utilisation of harm reduction practices, can inform public health messaging.
methodsWe recruited 26 participants at least 18 years of age, reporting three or more occasions of GHB use in the past 12 months, via a national social media campaign and snowball methods. Semi-structured interviews were conducted via video conference, and analysed using a thematic framework analysis.
resultsNineteen women (73%) and seven men (27%), mean age 29 years (standard deviation 7 years) completed interviews. Participants described three distinct patterns of occasional, regular, or daily GHB use. Across these patterns, four key themes emerged: (1) Escapism: participants used GHB to manage mental health symptoms, counteract stimulant effects of methamphetamine, enhance self-confidence, and facilitate sex. Women described using GHB to alleviate body consciousness/dysmorphia. (2) Diverse understandings and experiences of overdose: participants described a spectrum from mild to life-threatening toxicity. Notably, dosing GHB to achieve unconsciousness (intentional overdose) was a theme that dovetailed with boundary play in our sample. Misconceptions included using stimulants to counter GHB toxicity. Fear of police involvement delayed or prevented help seeking. (3) Stigma: Participants reported stigma from peers who use and do not use drugs. (4) Gendered harm reduction practices: A set of practices centred on women protecting women from harms associated with GHB use emerged, with narrations of heightened vigilance and protective behaviours to reduce risks of sexual violence.
conclusionIn our heterosexual sample of people who use GHB in Australia, we identified novel aspects of GHB use characterised by escapism, intentional risk-taking, and gendered harm reduction strategies, while stigma featured alongside GHB use. Findings highlight gaps in public health education, particularly regarding intentional dosing towards unconsciousness, misconceptions about overdose management, and barriers to help seeking. Targeted, context-specific harm reduction and mental health interventions responsive to these experiences are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.